SPOTLIGHT: Insurers hike co-pays for expensive meds

Health insurers are passing on the high cost of some meds to patients, asking them to pay up to one-third the price of expensive drugs; the policies affect drugs for such serious illnesses as cancer, multiple sclerosis, and rheumatoid arthritis, and they apply even to meds without cheaper equivalents. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.